Restylane Benefit Over Collagen Will Show In Data, Not Labeling Terms – CEO
This article was originally published in The Gray Sheet
Executive Summary
Pivotal trial data inclusion in Medicis/Q-Med's Restylane labeling will be sufficient to demonstrate superiority over Inamed's Zyplast, should it earn FDA approval, according to Medicis
You may also be interested in...
Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety
FDA's regulation of Genzyme's hyaluronic acid-based Synvisc osteoarthritic knee pain treatment could offer a precedent for labeling of the firm's Hylaform HA dermal filler
Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety
FDA's regulation of Genzyme's hyaluronic acid-based Synvisc osteoarthritic knee pain treatment could offer a precedent for labeling of the firm's Hylaform HA dermal filler
Facial Implant Panel Endorsement Masks Study Bias Concerns
Potential biases resulting from the use of patients as their own controls within Q-Med's Restylane pivotal trial drew criticism during FDA panel review of the hyaluronic acid-based dermal filler Nov. 21